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Abstract
Evidence based use of herbal medicines has a positive implication for both users and society. In this study, component plant
materials of a traditional Ghanaian polyherbal skin product comprising Eugenia caryophyllata, Zanthoxylum zanthoxyloides Tridax
procumbens, Psidium guajava and Alchornea cordifolia and used in the management of superficial skin infections was evaluated
to establish their contribution to the overall therapeutic activity of the product. Each of the five (5) plant s was subjected to an in
vitro antimicrobial assay using the microtitre broth technique followed by an interactive combination assay for plants demonstrating
noteworthy antimicrobial activity (MIC≤ 1.0 mg/ml). Test strains included Staphyloccocus aureus, Candida albicans, Trichophyton
rubrum, Epidermophyton floccusum and Microsporum canis. Eugenia caryophyllata, Zanthoxylum zanthoxyloides and Alchornea
cordifolia showed better activity than Psidium guajava, Tridax procumbens and the Total Crude Extract ( combination of the 5
extracts). The b inary combination of Eugenia caryophyllata and Alchornea cordifolia indicated synergistic and additive activity
against all the test strains. An improved biological activity was also observed when a mixture of the two ( 2 ) plants at a ratio of
Eugenia caryophyllata 60 % (w /w ) and Alchornea cordifolia 40 % (w /w ) was assayed. A f ollow up pilot clinical study established
that this new recipe was clinically effective but of lower therapeutic effect compared to the original product. In conclusion, t he
original formulation of the product may be preferred because of the shorter duration of treatment which reduces the risk of harms
and cost of treatment.
Keywords: Antimicrobial screening; Dermatophytes; Herbal medicine; Interactive combination study; Polyherbal product; Tradi-
tional Ghanaian Medicine
Introduction
The use of herbal medicines and their products among the
Ghanaian populace is on the increase. Generally, socio-religious
compatibility, affordability and accessibility have been well dis-
cussed as factors accounting for this preference. The absence of
toxicity and better efficacy are also factors that have been re-
ported as attributable for this trend in usage, although these two
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theories are very contentious. The related issues about the tox-
icity and unproven efficacy of herbal medicines has increased
the calls for the scientific validation of all herbals. Practition-
ers therefore have an obligation in the formulation and use of
herbal medicines; especially when the products are made from
two or more plant materials, that there is a reliance on scientific
evidence for such multiple combinations [1].
The evidence - based use of herbal medicines has positive im-
plications for both users and society. For society, the sustainable
exploitation of these finite resources will ensure the sustenance
of the communities which have their livelihood and existence
directly linked to the conservation of their flora [2]. The con-
©2019 Advanced Research Journals
Thomford et al. Submitted to International Journal of Phytomedicine Page 2 of 7
servation of medicinal plants is thus a very important issue of
international concern as the ever-increasing demand for herbal
medicines continues to put enormous pressure on the raw ma-
terials for herbal medicinal products (HMP). The protection of
such resources is critical for a country like Ghana where about
135,395 hectares of forest cover is lost each year through unreg-
ulated human activities [3].
The implications for users of such multi-component herbal
products are also seen in at least three ways. First, the risk of ad-
verse reactions and other unwanted side effects may be greatly
increased with an increase in the number of plant materials used
in a product [4]. A clear demonstration of the benefits of such
combinations must therefore be evident for such products if mul-
tiple ingredients are to be used. Secondly, reliance on scientific
evidence optimises the therapeutic benefits derived from these
products through correct dosing, which in turn reduces treatment
failures. Finally, t he cost of production of these medicines may
also be greatly reduced through such data with the economic
burden on clients also decreased due to the reduced cost of prod-
ucts.
The practice of herbal medicine in Ghana is undergoing a lot
of modernisation to increase the rational use of herbal medicines
through the scientific validation of the practice and its prod-
ucts. This study reports on one of these steps at ensuring that
herbal products are evidenced based. The product under study is
a Ghanaian polyherbal product and has been used for the man-
agement of superficial mycoses for more than 20 years with-
out any data about it. The formulation which originated from a
Ghanaian traditional healer is prepared as a combination of five
(5) plants: Eugenia caryophyllata, Zanthoxylum zanthoxyloides
Tridax procumbens, Psidium guajava and Alchornea cordifolia.
The product has been previously evaluated clinically in a ran-
domised control trial with a 10% (w /w ) concentration of the
product showing better activity than Whitfield’s ointment [5].
However, the use of multiple plant materials for the product was
of great concern because of the issues currently being raised
about the conservation of botanicals, the cost to users and ul-
timately its safety and efficacy profile. In view of this, an in vitro
antimicrobial assay was undertaken to establish the contribution
of each plant to the overall biological activity of the product and
propose a new recipe with similar or better activity than the orig-
inal formulation. This recipe was then tested in a pilot human
trial to establish its efficacy and safety.
Materials and Methods
Preparation of Plant Materials
The plants used in the original product comprised the dried leaf
of Alchornea cordifolia (Schum. & Thonn.) Muell.Arg. (Eu-
phorbiaceae) and Psidium guajava (Linn) (Myrtaceae); the dried
whole plant of Tridax procumbens (Linn) (Asteraceae), the dried
stem bark of Zanthoxylum zanthoxyloides (Lam) (Rutaceae)
and the dried flower buds of Eugenia caryophyllata (Thumb)
(Myrtaceae). All plant parts were dried under shade for two
weeks at an ambient temperature after authentication by a tax-
onomist at the Centre for Plant Medicine, Mampong-Akwapem
and voucher specimen deposited at the institution ’s herbarium
(Table 1.0). Hydro-ethanolic extracts of the materials were ob-
tained by macerating 1.0 kg of the powdered plant material in
5.0 litres of 70 % (v /v ) ethanol for 3 days and then filtering.
Ethanol was recovered using the Rotary evaporator and the re-
maining fluid extract lyophilised to obtain a dry powder. The
original formulation for the product was also obtained by com-
bining the five (5) plant materials using a proprietary formula to
obtain a combination labelled as the Total Crude Extract (TCE).
Preparation of Cultures and Test Organisms
The media preparation and process of culturing of pathogens
used in the experiments were performed as detailed in the Na-
tional Committee for Clinical Laboratory Services (NCCLS)
guidelines [6]. The microorganisms chosen for analysis were se-
lected based on their dermatological relevance. Microorganism
strains that were used are of the American Type Culture Col-
lection (ATCC) strains. Three dermatophytes and one yeast or-
ganism with dermatological importance were selected for the as-
says and included: Trichophyton rubrum (ATCC 10218), Epider-
mophyton flocossum (ATCC 9664), Microsporum canis (ATCC
36299) and the yeast Candida albicans (ATCC 10231) were also
tested.Staphylococcus aureus (ATCC 25923) was selected as the
bacterial strain.
Determination of MIC of Plant Extracts and Total Crude
Product
A serial micro-dilution assay using the micro-titre plate dilution
technique was used to determine the Minimum Inhibitory Con-
centration (MIC) values for the extracts of the component plant
materials and the Total Crude Extract (TCE). Using aseptic ma-
nipulation, 100 µl of Phosphate Buffer Saline (PBS) was placed
in each well of a 96 well micro-titre plate. The plant extracts at
starting concentrations of 100 mg/ml in 2% Dimethyl Sulfoxide
(DMSO) were transferred to the first column of the micro-titre
plate. Serial dilutions were performed on each plate, and there-
after the cultures with an approximate inoculum size of 1× 106
colony forming units/ml (CFU/ml) were introduced. A volume
of 100 µl of the culture was added to all the wells. Tests were
performed in duplicates. Each plate was subsequently sealed
with a sterile adhesive sealing film. All micro-titre plates were
incubated under the suitable conditions. Ketoconazole (Sigma
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Aldrich, USA) was used as the reference agent for the fungal
strains and Ciprofloxacin (Sigma Aldrich, USA) for the bacte-
rial strain.
Detection of Microbial Activity
Testing for bacterial and fungal growth after incubation was
done by adding 40 µl (0.04 % w /v ) of p -iodonitrotetrazolium
chloride (INT) (Sigma Aldrich, USA) to each well of the plate.
The plates were subsequently incubated again for 2-4 hrs for the
bacterial strain and 24-36 hrs for the fungal strains. The devel-
opment of a pink to reddish colour in the well after incubation
was recorded as a microbial growth. Minimum Inhibitory Con-
centration (MIC) was defined as the lowest concentration of the
plant extract that showed no visible microbial growth.
Table 1 List of Plants used in the Product, Local Ghanaian Name,
Common Names and Voucher Specimen Number

























































Selection of Plant Extracts with Significant Antimicrobial
Activity
Individual plant extracts showing significant antimicrobial activ-
ity defined as MIC of < 1.00 mg/ml against half of the test mi-
croorganisms were then selected for an interactive combination
study.
Interactive Combination Studies
The potential synergistic, additive, non-interactive (indifferent)
or antagonistic interaction between the selected plants extracts
were investigated using two approaches. First, the component
plant extracts at a starting concentration of 100 mg/ml were
mixed in ratios of 1:1. The MIC values were determined for each
combination to establish the interaction and the sum of the Frac-
tional I nhibitory Concentration (
∑
FIC) was calculated for each
combination using the following equation;
FIC (i) = MIC (a) in combination with (b) / MIC (a) indepen-
dently
FIC (ii) = MIC (b) in combination with (a) / MIC (b) inde-
pendently
(i) and (ii) in this study represents the different plants in com-
bination. The sum of the FIC, known as the FIC index was thus
calculated as
∑
FIC = FIC (i) + FIC (ii). Results were classified
as either synergistic (≤ 0.50), additive (0.50-1.00), indifferent
(>1.00-4.00) or antagonistic (>4.00) [7].
The combinations with notable interactions, defined as syn-
ergistic activity for more than half of the test, were further in-
vestigated at various ratios against the selected pathogens. The
MIC assay was conducted on four (4) ratio combinations i.e. 80
%: 20 %; 60 %: 40 %; 40 %:60 % and 20 %: 80 % f or the even-
tual product. The results were then plotted on an isobologram
using Sigma Plot
®
Software (Version 11.0), allowing for a figu-
rative representation of the interaction s. The isobolograms were
interpreted by examining the data points of the ratio where the
MIC for each concentration is determined in relation to the in-
dependent MIC ’ s. Data points falling below or on the 0.50 line
on the isobologram were interpreted as synergistic. Points be-
tween 0.50 and/or on the 1.00 line were interpreted as additive
and points > 1.00 -≤ 4.00 were defined as either non-interactive
or antagonistic for points >4.0 [8]. Positive and negative con-
trols were included in all assays which were also undertaken in
duplicate and the mean values noted.
Pilot Clinical Study of the Reformulated Product
Interventional Products: Based on the outcome of t he in vitro
interactive study, a reformulated product with a new recipe was
developed and labelled RF-2016 . The strength of this product
was 5% (w /w). The reformulated product RF-2016 served as
the test product and the original formulation EAF-2011 as the
control.
Ethical Considerations and Trial Design
The protocol employed for the study, the consent form and the
patient information sheet were reviewed and approved by the
ethics committee for human research of the Centre for Plant
Medicine Research, Mampong-Akuapem prior to trial initiation.
The trial was performed in accordance with the Declaration of
Helsinki and Good Clinical Practice (WHO, 2001). Written in-
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formed consent from every study subject was obtained prior to
the trial-related activities; the consent forms were retained by the
investigators.
A pilot trial in which subjects were randomised in a ratio of
2:1 for the 5% (w/w)RF-2016 and 10% (w /w)EAF-2011 respec-
tively was undertaken. Randomisation was achieved by making
participants pick (without replacing), from 15 folded papers with
10 labelled for 5% (w/w)RF-2016 and 5 labelled for 10% (w/w)
EAF-2011. Allocation was done to attain this ratio at the end of
a 15th recruitment.
Inclusion and Exclusion Criteria
Participants included in the study were males and females be-
tween the ages of 8 and 45 years, clinically diagnosed with
any of the superficial fungal infections. Exclusion criteria also
comprised any individual who had been diagnosed kidney or
liver dysfunction, pregnant women, immunocompromised pa-
tients and individuals on any orthodox medications that had the
potential to affect the outcome of the trial such as corticos-
teroids and immunomodulating agents. Acutely ill-individuals
were also exempted from the study.
Assessment of Efficacy and Drug Related Toxicity
Primary assessment of effectiveness and classification of ther-
apeutic response for each participant was done using a clini-
cal score. The assessment employed the Total Sign and Symp-
toms Score (TSSS) with modifications (Friedlander et al., 2002).
This is a rating using a four-point scale where; 0 - absent ; 1 -
mild ; 2 - moderate ; 3 - severe for each of the selected signs
and symptoms that are characteristic for the condition. In this
case pruritus, desquamation, erythema and the presence of vesic-
ular/popular features were used. Clinical effectiveness of the
products was defined as TSSS of 0 i.e. the absence of any signs
and symptoms from the participants. Adverse effects that may
be associated with the product was monitored using the WHO
adverse reaction checklist [9].
Results
Minimum Inhibitory Concentrations of Plant Extracts
Screened
All five (5) plants screened demonstrated some activity against
the test fungi and bacteria. The level of antimicrobial activity
demonstrated generally varied with the test organisms. MIC ’s
for Tridax procumbens were higher than the other plant extracts
tested (Table 2.0). The five (5) plant extracts also failed to show
any significant activity against S. aureus. However, the activ-
ity demonstrated by Alchornea cordifolia (MIC: 1.563 mg/ml),
Zanthoxylum zanthoxyloides (MIC: 1.563 mg/ml) and Eugenia
caryophyllata (MIC: 1.563 mg/ml) was better than Total Crude
Extract (MIC: 3.125 mg/ml) used in the formulation of the final
product.
Preliminary Interactive Combination Studies of the
Selected Plants
Three (3) plants: Eugenia caryophyllata, Zanthoxylum zanthoxy-
loides and Alchornea cordifolia were selected for the interac-
tive combination studies based on their MIC’s reported in Ta-
ble 2.0. Results for the binary and a triple combination are also
reported in Table 3.0 together with their sum of Fractional In-
hibitory Concentration (
∑
FIC) for the binary mixtures.
The combination of Eugenia caryophyllata and Zanthoxylum
zanthoxyloides in a ratio of 1:1 was additive against all the test
strains except S. aureus. The combination was non-interactive
against the latter with
∑
FIC of 4.0. Z. zanthoxyloides and A.
cordifolia were antagonistic in effect when tested against C. al-
bicans (
∑
FIC: 59.94) and non-interactive against the four (4)
fungi and bacterial strains (Table 2.0 ). The combination of A.
cordifolia and E. caryophyllata was synergistic in effect against
S. aureus and additive against M. canis, C. albicans and E. flo-
cossum from the
∑
FIC (Table 3.0). A non-interactive effect was
noted when the combination was tested against E. flocossum.
The activity demonstrated by the MIC of the triple combination
of E. caryophyllata, Z zanthoxyloides and A. cordifolia was also
not better than the three (3) binary combinations.
Interactive Combination Studies for Alchornea cordifolia
and Eugenia caryophyllata
Results for the interactive study of Alchornea cordifolia and Eu-
genia caryophyllata in varying percentages showed the combi-
nation of A. cordifolia 40 % (w /w ) with E. caryophyllata 60 %
(w /w) as most efficacious against all the microbial strains tested.
The combination demonstrated synergistic activity against S. au-
reus, C. albicans, M. canis and T. rubrum (Figure 1.0). An ad-
ditive effect was recorded in the test against E. flocossum. The
other combin ations were also synergistic or additive in effect
when tested against C. albicans. Other notable combinations are
listed: the synergistic effect of the A. cordifolia 20 % (w/w ) with
E. caryophyllata 80 % (w/w ) against T. rubrum,Additive effect
of A. cordifolia 20 % (w /w ) with E. caryophyllata 80 % (w/w )
and the 60 % (w/w ) A. cordifolia with 40 % (w /w ) E. caryophyl-
lata against E. flocussum and the additive activity of A. cordifolia
60 % (w/w ) with E. caryophyllata 40 % (w/w ) against M. canis.
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Table 2 Average MIC (mg/ml) for the plant extracts screened using the micro-dilution assay
Plant Extract T. rubrum E. flocossum M. canis C. albicans S. aureus
A. cordifolia 3.125 0.0781* 0.0781* 0.0781* 1.563
T. procumbens 25.00 3.125 3.125 1.563 6.25
Z. zanthoxyloides 6.250 0.0391* 0.0781* 0.0391* 1.563
P. guajava 3.125 0.078* 3.125 1.563 6.25
E. caryophylata 0.0781* 0.0391* 0.0781* 0.0781* 1.563
Ketoconazole 15 × 10−2 85 × 10−3 56 × 10−3 1.05 × 10−2
Ciprofloxacin - - - - 25 × 10−3
Total Crude Extact 1.563 3.125 0.0781* 3.125 3.125
* Indicates plant extracts with significant antimicrobial activity
Table 3 MIC (mg/ml) [
∑
FIC] for binary combinations of A. cordifolia, Z. zanthoxyloides and E. caryophyllata at a ratio of 1:1
Plant Extract T. rubrum E. flocossum M. canis C. albicans S. aureus
E. caryophyllata & Z. zanthoxyloides 0.0391 [0.506] 0.0391 [1.00] 0.0781 [1.00] 0.0195 [0.748] 3.125 [4.0]
Z. zanthoxyloides &A. cordifolia 6.250 [3.00] 0.0391 [1.50] 0.0781 [2.00] 1.563 [59.94] 1.563 [2.0]
A. cordifolia & E. caryophyllata 0.0391 [0.511] 0.0195 [0.748] 0.0195 [0.499] 0.0195 [0.499] 0.0781 [0.075]
A.cordifolia + E. caryophyllata + Z. zanthoxyloides 1.563 1.563 3.125 1.563 0.0781
Figure 1 Isobologram of Alchornea cordifolia and Eugenia caryophyllata in varying combinations against the 5 test organisms. Data points falling
below or on the 0.50 (Green Line) were interpreted as synergistic. Points between 0.50 and/or on 1.00 (Red Line) were interpreted as additive and
points >1.00 were defined as non-interactive
Pilot Clinical Study
A total of fifteen (15) participants were involved in the study.
The mean age of participants was 14.40 (± 3.96) for participants
randomised to the control treatment of 10 EAF-2011 and 11.50
(± 4.31) for participants in the reformulated product group. De-
mographical data of subjects is summarised as table 4.0.
Treatment Efficacy
Baseline TSSS between the 2 groups were comparable: EAF-
2011 group had a TSSS of 9.6 (±2.3) with the reformulated
product recording a mean TSSS of 8.4 (±2.55). The control







14.40 (3.96) 11.50 (4.31)
Males (%) 4 (80) 8 (80)
Females
(%)
1 (20) 2 (20)
treatment demonstrated better activity than the reformulated
product. This group had 5 (100.0 %) of the treated subjects
achieving complete cure by day 56 compared to 1 (10.0 %) for
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the reformulated product. The percentage cure for the latter in-
creased to 6 (60.0 %) on day 84 using the intention to treat
(ITT) population and 75.0 % without the ITT population. The
difference between the two treatments is shown in figure 2.0.
The study also had two (2) participants from the reformulated
product dropping out due to loss on follow up.
Figure 2 Effect of the Reformulated product (RF-2013) on the TSSS
of participants with time (a), calculated as the area under the curve
(AUC) (b). Data is presented as mean (SD) compared with the
control (an independent t-test at an α-level of 1% showed a
significant difference between the treatments; *†p < 0.05, CI: (-0.123
to 5.723)
Safety Analysis
The safety analysis of the reformulated herbal product and the
control treatment involved an active surveillance of harms. The
surveillance employed the WHO checklist for adverse drug ef-
fects. Participants receiving both herbal treatments did not report
any adverse effects during the study period of three (3) months.
Discussion
Although herbal medicines continue to receive praise for their
potential in meeting the health needs of developing countries,
there are still valid concerns about these health products. Un-
derlying these concerns is the lack of valid scientific evidence
to back their therapeutic use. This situation is rife in develop-
ing countries like Ghana where the evidence for use of most
botanical agents is still based on folklore. A shift towards an
evidenced-based practice will be very beneficial to all stakehold-
ers.
This report sought to validate the recipe for the formulation
which is used to treat skin infections especially those of fungal
origin. Re-evaluation of the component plant materials used in
the production of the polyherbal product did indicate the rele-
vance of each starting material. Generally positive activity was
noted for each of the plant materials and the total crude extract
tested. Eugenia caryophyllata proved most efficacious with sig-
nificant activity against all the fungal strains tested. Zanthoxylum
zanthoxyloides and Alchornea cordifolia al so showed signifi-
cant activity. These findings confirm other documented evidence
on the antimicrobial activity of the three (3) plants [10–12].
On the contrary, although there have been reports indicating
the antifungal activity of Psidium guajava and Tridax procum-
bens against the test strains [13, 14], in this report the activity
shown could not be described as significant ; Typical factors such
as the variability in chemical constituents can be responsible for
this difference in activity.
Significantly, the in vitro activity of the individual starting
materials when compared with that of the total crude extract in-
dicated a possible advantage of using a single plant formulation.
However, the possibility of obtaining a synergistic action when
medicinal plants are used in combination informed the interac-
tive combination study [15, 16].
Minimum inhibitory concentrations reported in Table 2.0 also
showed the binary combinations as generally having better ac-
tivity than that of the triple combination of Eugenia caryophyl-
lata, Zanthoxylum zanthoxyloides and Alchornea cordifolia. The
combination of Eugenia caryophyllata and Alchornea cordifo-
lia indicated synergistic and additive activity against all the mi-
croorganisms. The combination was therefore considered a bet-
ter option than the mixtures of Zanthoxylum zanthoxyloides with
Alchornea cordifolia and Eugenia caryophyllata in combination
with Zanthoxylum zanthoxyloides.
The therapeutic effect for the combination of Eugenia
caryophyllata and Alchornea cordifolia was also demonstrated
to be optimum when the two plant extracts are combined in
the ratio of 60 % (w /w ) and 40 % (w /w ) respectively. This
combination proved most efficacious as shown in Figure 1.0.
The 2 plants at that ratio was synergistic against Staphylococcus
aureus, Candida albicans, Microsporum canis and Trichophy-
ton rubrum and could be recommended as the most suitable
combination despite showing only additive effect against Epi-
dermophyton flocossum.
The mixture of Alchornea cordifolia 40 % (w/w) and Eugenia
caryophyllata 60 % (w/w) was thus proposed as the new recipe
for the product based on the synergistic activity demonstrated
against most of the microorganisms tested.
In the pilot clinical study of this new formulation, participants
attaining the primary outcome of complete cure for the 10 %
(w/w)EAF-2011 was 5 (100.0 %) compared to the 6 (60.0 %) for
the 5 % (w /w) RF-2016. This cure rate for RF-2016 increases
to 75.0 % when analysis is done without the withdrawals from
the study. The change in TSSS i s indicated by the plot (Figure
2.0a) and the area under the curve ( Figure 2.0 b). However, the
time taken to achieve the primary outcome (Figure 2.0a) will
make the 10 % (w/w ) EAF-2011 the preferred treatment. The
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shorter time of exposure to the therapeutic agent reduces the risk
of harms and the cost of treatment for patients.
Despite the weight of the evidence being in favour of the 10
% (w/w ) EAF-2011, the reformulated product may still be ther-
apeutically relevant as the product was tested at a concentration
of 5 % (w/w). The therapeutic effect observed could be concen-
tration dependent as observed in the clinical trial of t he origi-
nal product ( EAF- 2011) 5. The results of this interactive study
indicate the potential for an improvement of the product when
the combination of Eugenia caryophyllata 60 % (w/w) and Al-
chornea cordifolia 40 % (w/w) is used as the new recipe for the
formulation.
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